phosphosolutions

981 products

Showing 265 - 288 of 981 products
View
Western blot image of human A431 cells treated with Calyculin A (100 nM) for 30 min. Blot lanes were untreated (lanes 1, 3, & 5) or treated with lambda phosphatase (lanes 2, 4, & 6) then were probed with anti-EGFR (a.a. 961-972) (lanes 1 & 2), anti-EGFR (Ser-967) (lanes 3 & 4), and anti-EGFR (Ser-1142) (lanes 5 & 6).Immunocytochemical labeling in A431 cells untreated or treated with Calyculin A (50 nM) for 15 min. Cells were labeled with anti-EGFR (a.a. 961-972) or anti-EGFR (Ser-1142) antibodies. The specificity of labeling was demonstrated for each antibody by blocking the signals with their respective blocking peptides, EGFR (a.a. 961-972) (EX1875) and phospho-EGFR (Ser-1142) (EX1935).
PhosphoSolutions Anti-EGFR (Ser-1142), Phosphospecific Antibody
$340
Western blot image of human A431 cells treated with Calyculin A (100 nM) for 30 min. Blot lanes were untreated (lanes 1, 3, & 5) or treated with lambda phosphatase (lanes 2, 4, & 6) then were probed with anti-EGFR (a.a. 961-972) (lanes 1 & 2), anti-EGFR (Ser-967) (lanes 3 & 4), and anti-EGFR (Ser-1142) (lanes 5 & 6).Immunocytochemical labeling in A431 cells untreated or treated with Calyculin A (50 nM) for 15 min. Cells were labeled with anti-EGFR (a.a. 961-972) or anti-EGFR (Ser-967) antibodies. The specificity of labeling was demonstrated for each antibody by blocking the signals with their respective blocking peptides, EGFR (a.a. 961-972) (EX1875) and phospho-EGFR (Ser-967) (EX1915).
PhosphoSolutions Anti-EGFR (Ser-967), Phosphospecific Antibody
$340
Western blot image of human A431 cells untreated (lanes 1 & 3) or treated with EGF (100 ng/ml) for 5 min. The blot was probed with anti-EGFR (Tyr-1101) monoclonal antibody (lanes 1 & 2) or anti-EGFR (Cytoplasmic) monoclonal antibody (lanes 3 & 4).Immunocytochemical labeling in A431 cells untreated or treated with EGF (100 ng/ml) for 5 min. The cells were labeled with mouse monoclonals anti-EGFR (EM1661) and anti-EGFR (Tyr-1101) (EM1991).
PhosphoSolutions Anti-EGFR (Tyr-1101), Phosphospecific Antibody
$370
Western blot of mouse testes lysate showing specific immunolabeling of the ~46 kDa eukaryotic initiation factor 4A2, eIF4A2, protein.
PhosphoSolutions Anti-eIF4A2 Antibody
From $160
Choose options
PhosphoSolutions Anti-ElF5a2 Antibody
$445
Western blot of recombinant Elk-1 showing specific immunolabeling of the ~46 kDa Elk-1 phosphorylated at Ser383 in the right lane (-). Phosphospecificity is shown in the left lane (+) where immunolabeling is blocked by preadsorption of the phosphopeptide used as the antigen, but not by the corresponding non-phosphopeptide (not shown).
PhosphoSolutions Anti-Elk-1 (Ser383) Antibody
From $160
Choose options
Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NM2211) and rabbit polyclonal eNOS (NP2281) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
PhosphoSolutions Anti-eNOS (C-terminal region) Antibody
$370
Western blot analysis of human umbilical vein endothelial cells treated with calyculin A (100 nM) for 30 min. (lanes 1, 3, 5 & 7) then the blots were treated with lambda phosphatase (lanes 2, 4, 6 & 8). The blots were probed with anti-endothelial nitric oxide synthase (eNOS) (C-terminal region) (lanes 1 & 2), anti-eNOS (Ser-632) (lanes 3 & 4), anti-eNOS (Ser-1177) (lanes 5 & 6) and anti-eNOS (a.a. 1172-1181) (lanes 7 & 8).
PhosphoSolutions Anti-eNOS (C-terminal region) Antibody
$285
Western blot analysis of human umbilical vein endothelial cells treated with calyculin A (100 nM) for 30 min. (lanes 1, 3, 5, & 7) then the blots were treated with lambda phosphatase (lanes 2, 4, 6, & 8). The blots were probed with anti-endothelial nitric oxide synthase (eNOS) (C-terminal region) (lanes 1 & 2), anti-eNOS (Ser-632) (lanes 3 & 4), anti-eNOS (Ser-1177) (lanes 5 & 6), or anti-eNOS (a.a. 1172-1181) (lanes 7 & 8).
PhosphoSolutions Anti-eNOS (Ser-1177), Phosphospecific Antibody
$340
Western blot analysis of human umbilical vein endothelial cells stimulated with Calyculin A and untreated (lanes 1, 3, 5) or treated (lanes 2, 4, 6) with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).
PhosphoSolutions Anti-eNOS (Ser-632), Phosphospecific Antibody
$340
Western blot analysis of human umbilical vein endothelial cells stimulated with pervanadate (1 mM) for 30 min. (lanes 1, 3, & 5) then the blot was treated with alkaline phosphatase (lanes 2, 4, & 6). The blots were probed with anti-eNOS monoclonal antibody (NM2211; lanes 1 & 2), anti-eNOS (Tyr-657) phospho-specific antibody (NP4031; lanes 3 & 4), or anti-eNOS polyclonal antibody (NP2281; lanes 5 & 6).Immunocytochemical labeling of nNOS phosphorylation in rat PC12 cells differentiated with NGF. The cells were probed with mouse monoclonal (mAb) nNOS (NM4011), and rabbit polyclonal (pAb) nNOS (C-terminal region), nNOS (Tyr-895)/eNOS (Tyr-657), and nNOS (Tyr-1326)/iNOS (Tyr-1055). The antibodies were detected using appropriate secondary antibody conjugated to DyLight® 594.
PhosphoSolutions Anti-eNOS (Tyr-657)/nNOS (Tyr-895), Phosphospecific Antibody
$340
Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NM2211) and rabbit polyclonal eNOS (NP2281) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
PhosphoSolutions Anti-eNOS Antibody
$285
Western blot of native lysates including human EpCAM extracellular region (lane 1 & 6), MCF7 breast carcinoma (lane 2 & 7), A431 skin adenocarcinoma (lane 3 & 8), NCI-H1915 lung carcinoma (lane 4 & 9), and NCI-H446 lung carcinoma (lane 5 & 10). The blot was probed with mouse monoclonal anti-EpCAM (EM0391) (lanes 1-5) and mouse monoclonal anti-EpCAM (EM0421) (lanes 6-10) at 1:1000 each.Immunocytochemical labeling of EpCAM in aldehyde fixed human NCI-H1915 lung carcinoma cells. The cells were labeled with mouse monoclonal anti-EpCAM (EM0391). The antibody was detected using goat anti-mouse Ig:DyLight® 594.
PhosphoSolutions Anti-EpCAM (Extracellular region) Antibody
$370
Western blot of native lysates including human EpCAM extracellular region (lane 1 & 6), MCF7 breast carcinoma (lane 2 & 7), A431 skin adenocarcinoma (lane 3 & 8), NCI-H1915 lung carcinoma (lane 4 & 9), and NCI-H446 lung carcinoma (lane 5 & 10). The blot was probed with mouse monoclonal anti-EpCAM (EM0391) (lanes 1-5) and mouse monoclonal anti-EpCAM (EM0421) (lanes 6-10) at 1:1000 each.Immunocytochemical labeling of EpCAM in aldehyde fixed human NCI-H1915 lung carcinoma cells. The cells were labeled with mouse monoclonal anti-EpCAM (EM0421). The antibody was detected using goat anti-mouse Ig:DyLight® 594.
PhosphoSolutions Anti-EpCAM (Extracellular region) Antibody
$370
Western blot of human MDA-MB-231 breast carcinoma (lane 1), A431 epidermoid carcinoma (lane 2), NCI-H2052 epithelioid mesothelioma (lane 3), and A549 lung carcinoma (lane 4). The blot was probed with mouse monoclonal anti-EphA2 (EM0491) at 1:1000.Immunocytochemical labeling of EphA2 in aldehyde fixed human MDA-MB-231 breast carcinoma cells. The cells were labeled with mouse monoclonal anti-EphA2 (EM0491). The antibody was detected using goat anti-mouse DyLight® 594.
PhosphoSolutions Anti-EphA2 (Extracellular region) M049 Antibody
$370
Western blot of human MDA-MB-231 breast carcinoma (lane 1), A431 epidermoid carcinoma (lane 2), NCI-H2052 epithelioid mesothelioma (lane 3), and A549 lung carcinoma (lane 4). The blot was probed with mouse monoclonal anti-EphA2 (EM0601) at 1:500.Immunocytochemical labeling of EphA2 in aldehyde fixed human MDA-MB-231 breast carcinoma cells. The cells were labeled with mouse monoclonal anti-EphA2 (EM0601). The antibody was detected using goat anti-mouse DyLight® 594.
PhosphoSolutions Anti-EphA2 (Extracellular region) M060 Antibody
$370
Representative Standard Curve using mouse monoclonal anti-EphA2 (EM0881) for ELISA capture of human recombinant EphA2 extracellular region with a His-tag. Captured protein was detected by suitable anti-His-tag antibody followed by appropriate secondary antibody HRP conjugate.Immunocytochemical labeling of EphA2 in aldehyde fixed human MDA-MB-231 breast carcinoma cells. The cells were labeled with mouse monoclonal anti-EphA2 (EM0881). The antibody was detected using goat anti-mouse DyLight® 594.
PhosphoSolutions Anti-EphA2 (Extracellular region) M088 Antibody
$370
Western blot analysis of human umbilical vein endothelial cells untreated (lanes 1, 3, 5, & 7) or treated with pervanadate (1 mM) for 30 min. (lanes 2, 4, 6, & 8). The blot was probed with anti-EphA4 (N-terminal region) (lanes 1 & 2), anti-EphA4 (Tyr-779) (lanes 3 & 4), anti-EphA4 (Tyr-602) (lanes 5 & 6), or anti-EphA4 (C-terminal region) (lanes 7 & 8).
PhosphoSolutions Anti-EphA4 (C-terminal region) Antibody
$340
Western blot analysis of human umbilical vein endothelial cells untreated (lanes 1, 3, 5, & 7) or treated with pervanadate (1 mM) for 30 min. (lanes 2, 4, 6, & 8). The blot was probed with anti-EphA4 (N-terminal region) (lanes 1 & 2), anti-EphA4 (Tyr-779) (lanes 3 & 4), anti-EphA4 (Tyr-602) (lanes 5 & 6), or anti-EphA4 (C-terminal region) (lanes 7 & 8).Western blot image of various mouse and human HCC cell lines expressing EphA4 (Cat. EM2801, 1:1000). Image from publication CC-BY-4.0. PMID: 38307859
PhosphoSolutions Anti-EphA4 (N-terminal region) Antibody
$340
Paraformaldehyde-fixed zebrafish embryos were probed with anti-EphA4 (Tyr-602) (EP2731) then detected using Alexa Fluor 647 goat anti-rabbit. Arrows show labeling of somite boundaries and the notochord. (Image provided by Dr. Scott Holley at the Department of Molecular, Cellular and Developmental Biology, Yale University.)Western blot analysis of human umbilical vein endothelial cells untreated (lanes 1, 3, 5, & 7) or treated with pervanadate (1 mM) for 30 min. (lanes 2, 4, 6, & 8). The blot was probed with anti-EphA4 (N-terminal region) (lanes 1 & 2), anti-EphA4 (Tyr-779) (lanes 3 & 4), anti-EphA4 (Tyr-602) (lanes 5 & 6), or anti-EphA4 (C-terminal region) (lanes 7 & 8).
PhosphoSolutions Anti-EphA4 (Tyr-602) [conserved site], Phosphospecific Antibody
$340
Western blot analysis of human umbilical vein endothelial cells untreated (lanes 1, 3, 5, & 7) or treated with pervanadate (1 mM) for 30 min. (lanes 2, 4, 6, & 8). The blot was probed with anti-EphA4 (N-terminal region) (lanes 1 & 2), anti-EphA4 (Tyr-779) (lanes 3 & 4), anti-EphA4 (Tyr-602) (lanes 5 & 6), or anti-EphA4 (C-terminal region) (lanes 7 & 8).
PhosphoSolutions Anti-EphA4 (Tyr-779) [conserved site], Phosphospecific Antibody
$340
Western blot analysis of human A431 cells untreated (lanes 1 & 3) or treated with pervanadate (1 mM) for 30 min. (lanes 2 & 4). The blot was probed with anti-Ephexin-1 (C-terminal region) (lanes 1 & 2) and anti-Ephexin-1 (Tyr-87) (lanes 3 & 4).Immunocytochemical labeling of phosphorylated Exphexin-1 in pervanadate-treated mouse C2C12. The cells were labeled with rabbit polyclonal Ephexin-1 (C-terminal region) and Ephexin-1 (Tyr-87) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
PhosphoSolutions Anti-Ephexin-1 (C-terminal region) Antibody
$340
Western blot analysis of human A431 cells untreated (lanes 1 & 3) or treated with pervanadate (1 mM) for 30 min. (lanes 2 & 4). The blot was probed with anti-Ephexin-1 (C-terminal region) (lanes 1 & 2) and anti-Ephexin-1 (Tyr-87) (lanes 3 & 4).Immunocytochemical labeling of phosphorylated Exphexin-1 in pervanadate-treated mouse C2C12. The cells were labeled with rabbit polyclonal Ephexin-1 (C-terminal region) and Ephexin-1 (Tyr-87) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
PhosphoSolutions Anti-Ephexin-1 (Tyr-87), Phosphospecific Antibody
$340
Western blot of rat testes lysate showing specific immunolabeling of the ~46 kDa EphrinB phosphorylated at Tyr298 in the first lane (-). Phosphospecificity is shown in the second lane (+) where immunolabeling is completely eliminated by blot treatment with lambda phosphatase (λ-Ptase, 1200 units for 30 min).
PhosphoSolutions Anti-EphrinB (Tyr298) Antibody
From $160
Choose options

Recently Viewed